Palantir Technologies (PLTR) has recently forged partnerships with Knightscope Inc. for entry into the U.S. federal marketplace and with Velocity Clinical Research to enhance clinical trial efficiency. These collaborations coincide with the company's 61% share price increase over the past quarter. This rise aligns with Palantir's heightened revenue growth guidance and positive earnings report, which showed increased sales and net income. Amid a generally buoyant stock market, where the Nasdaq reached record highs, Palantir's performance was further buoyed by its inclusion in prominent indexes and strategic alliances, reinforcing its growth trajectory amid a favorable market environment.